Oligonucleotide– tag –
-
Oligonucleotide Drug Delivery Shifts Beyond Liver-Targeting to Tissue-Specific Approaches for Muscle and CNS
GlobeNewswire Unknown Overview Oligonucleotide drug delivery is evolving significantly, moving from traditional liver-targeted strategies to tissue-specific approaches for extrahepatic organs like muscle and the central nervous system (C... -
Chemoenzymatic Ligation Offers Scalable Solution to Nucleic Acid Therapeutics Manufacturing Bottlenecks, Surpassing Solid-Phase Synthesis Limits
The Medicine Maker Unknown Overview A new chemoenzymatic ligation technology is emerging as a scalable solution to the manufacturing bottlenecks in nucleic acid therapeutics, such as siRNA and mRNA. This approach efficiently assembles ol... -
U.S. FDA Approves Pfizer and BioNTech’s XFG-Adapted COVID-19 Vaccine, Aligned with 2026 Fall Vaccination Guidance
Pfizer USA Overview Pfizer and BioNTech have received U.S. FDA approval for their XFG-adapted COVID-19 vaccine. This approval aligns with the FDA's guidance on the recommended composition for COVID-19 vaccines to be used in the United St... -
AusperBio Secures $120M Series C Funding to Advance Phase 3 for Chronic Hepatitis B ASO Therapy AHB-137 and Accelerate Au-HALO™ Platform’s HBV siRNA Development
BioSpace Global Overview AusperBio Therapeutics has successfully completed a $120 million Series C financing round to vigorously advance its lead antisense oligonucleotide (ASO) therapy, AHB-137, through Phase 3 enrollment and towards co... -
siRNA Therapy Successfully Switches Off Harmful Genes: FDA-Approved Patisiran and Other Drugs for Hereditary Amyloidosis
Works in Progress Magazine UK Overview siRNA therapy is emerging as a promising treatment to slow or halt disease progression by temporarily silencing specific genes. For conditions like hereditary transthyretin amyloidosis, FDA-approved... -
Johns Hopkins’ N4-Acetylcytidine (ac4C) mRNA Platform Boosts Therapeutic Protein Production Beyond Industry Standard
Johns Hopkins Medicine USA Overview Scientists at Johns Hopkins Medicine have reported an experimental N4-acetylcytidine (ac4C) mRNA platform capable of delivering next-generation mRNA therapeutics for infectious diseases, cancer, and au... -
FDA Approves Novo Nordisk’s Pasatru for FOP, Accelerates Approval for Tudriqev Combination in Melanoma, and Greenlights mFLUSIVA mRNA Flu Vaccine
Drugs.com USA Overview In August 2026, the FDA approved several key new drugs. Novo Nordisk's Pasatru (garetosmab-grts) gained approval for adults with Fibrodysplasia Ossificans Progressiva (FOP). An accelerated approval was granted for ... -
Serina Therapeutics Highlights POZ Platform’s Potential to Enhance Efficacy and Safety of Small Molecule, RNA, and ADC Therapies
BioSpace USA Overview Serina Therapeutics announced its Q2 2026 financial and business updates, emphasizing the advancement of its wholly-owned pipeline for neurological and other indications, powered by its proprietary POZ Platform™. Th... -
Johns Hopkins Medicine Unveils Synthetic mRNA Platform for Faster, More Efficient Next-Gen Therapeutics
Johns Hopkins Medicine USA Overview Scientists at Johns Hopkins Medicine have announced the development of an experimental synthetic mRNA-based platform that holds the potential to deliver next-generation mRNA therapeutics for infectious... -
Nagoya University and Fujifilm Jointly Develop Novel LNP Delivery System for Enhanced Cyclic RNA Therapeutics
EurekAlert! Japan Overview Researchers from Nagoya University and Fujifilm have jointly developed a novel lipid nanoparticle (LNP) delivery system designed for efficient and stable intracellular delivery of circular RNA (cirRNA), a promi...
